The Endpoints 11: They’ve Got Mad Money And Huge Ambitions. It’s Time To Go Big Or Go Home
Read More
Posts by Mason Miller
Up And Down The Ladder: The Latest Comings And Goings
Read More
GSK’s Head Of Oncology Jumps To Boston Precision Medicine Startup
Read More
GSK’s Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion
Read More
In GSK’s Hoos, Scorpion Gains Oncology Pathfinder To Match Its $270m War Chest
Read More
GSK Oncology Exec Hoos Heads Back To Biotech As CEO Of Scorpion Therapeutics
Read More
Axel Hoos, The Keeper Of The Oncology Flame At Glaxosmithkline, Steps Away For His Next Challenge At Tiny Scorpion
Read More
Scorpion Therapeutics Strikes Major $162m Funding Round For ‘Precision Oncology 2.0™’
Read More
With Biotech Funding At ‘All-time High,’ Scorpion Scoops Up $162 Million
Read More
Gary Glick, Keith Flaherty Now Have $270m To Realize Their Vision For Precision Oncology 2.0™ — We’ll Just Have To Wait For The Details
Read More